<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00429494</url>
  </required_header>
  <id_info>
    <org_study_id>ID01-710</org_study_id>
    <nct_id>NCT00429494</nct_id>
  </id_info>
  <brief_title>GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients</brief_title>
  <official_title>Phase II Study of GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>TAP Pharmaceutical Products Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

        -  To determine the effectiveness of the 3-month depot leuprolide in inducing and
           maintaining secondary amenorrhea in patients undergo hematopoietic stem cell
           transplantation.

        -  To determine the incidence of regained ovarian function manifested as spontaneous
           restoration of menstruation and normalization of hormonal level in patients after
           transplantation and discontinuation of long-acting leuprolide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants in this study will be scheduled for hematopoietic stem cell transplantation
      at The University of Texas (UT) MD Anderson Cancer Center.

      Within two months before the transplantation, all participants will have a medical history,
      physical exam, and blood tests for ovarian function and platelet count. Participants will
      also need to have a gynecologic exam within one year before the transplantation.

      Participants who are eligible will receive the first dose of leuprolide as an injection into
      either the shoulder muscle or the thigh muscle during their first clinic visit. Participants
      who have low platelet count will be given platelet transfusion before the injection.

      Participants will then go on to have the transplantation as scheduled. Three months after the
      first dose of injection participants will have another clinic visit where blood tests for
      ovarian function will be performed. A second dose of the leuprolide will be given as an
      injection into the muscle at this visit. Again, if patients have low platelet count at that
      time, platelet transfusion will be given to patients before the injection. Participants will
      be given a checklist sheet for them to record any side effects while on the effect of
      leuprolide.

      Three months after the last dose of the injection, patients will have the option to start
      taking or to resume oral contraceptive pills. Those who choose not to take or to resume oral
      contraceptive pills will be followed and observed for the return of menstrual or monthly
      cycles. Those who choose to take or to resume oral contraceptive pills, has to stop taking
      oral contraceptive pills for a period of 3-6 months starting 1 year after transplantation for
      us to assess the ovarian function.

      During the period of follow up and observation of the return of menstruation, participants
      will be seen every two months either in the clinic or in the hospital if they are admitted.
      Participants will fill out questionnaires about their menstrual history at these visits. They
      should take about 15 minutes to complete. Blood tests for the ovarian function will also be
      done during these visits.

      This is an investigational study. The drug used in this study is commercially available and
      has been approved by FDA for use in prostate cancer patients. Its use in this study is
      investigational. About seventy-five patients will take part in this study. All will be
      enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Secondary Amenorrhea Following 3-month Depot Leuprolide</measure>
    <time_frame>6 months</time_frame>
    <description>Hormonal profile blood tests including follicle-stimulating hormone (FSH) test, luteinizing hormone (LH) and estradiol levels done every two months with menstruation questionnaire, starting three months after the injection of the second dose of leuprolide until the restoration of spontaneous menstruation or the presence of ovarian failure. Any unexpected vaginal bleeding or side effects during the period covered by leuprolide injection, which is 6 months, is recorded by participants in a monitoring checklist sheet given to them.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Amenorrhea</condition>
  <condition>Premature Ovarian Failure</condition>
  <condition>Ovarian Function Insufficiency</condition>
  <arm_group>
    <arm_group_label>Leuprolide Acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leuprolide Acetate 22.5 mg intramuscular (IM) injection 2 months before hematopoietic stem cell transplantation (HSCT) transplant and 3 months post-transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate</intervention_name>
    <description>22.5 mg IM injection 2 months before transplant and 3 months post-transplant.</description>
    <arm_group_label>Leuprolide Acetate</arm_group_label>
    <other_name>Leuprolide Acetate (delayed release)</other_name>
    <other_name>Lupron Depot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Questionnaires taking about 15 minutes to complete.</description>
    <arm_group_label>Leuprolide Acetate</arm_group_label>
    <other_name>Survey</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Stem cell infusion on Day 0.</description>
    <arm_group_label>Leuprolide Acetate</arm_group_label>
    <other_name>HSCT</other_name>
    <other_name>Stem Cell Transplant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hematopoietic stem cell transplantation candidate.

          -  Post-menarche female less than 40 years old.

          -  Premenopausal before the start of transplantation, or the start of oral contraceptive
             pills.

          -  Follicle-stimulating hormone (FSH) less than or equal to 20 IU/L and Luteinizing
             hormone (LH) less than or equal to 20 IU/L within 1 weeks of initiation of injection
             or the ovarian status is determined by Gynecology Oncology Service.

          -  Agree to stop any oral contraceptive pills for a period of 3-6 months starting 1 year
             post-transplant

        Exclusion Criteria:

          -  Breast cancer

          -  Ovarian cancer

          -  Pregnancy

          -  Hypersensitivity to any Gonadotropin-releasing hormone (GnRH) analogs
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naoto Ueno, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas (UT) MD Anderson Cancer Center official website</description>
  </link>
  <results_reference>
    <citation>Cheng YC, Takagi M, Milbourne A, Champlin RE, Ueno NT. Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patients. Oncologist. 2012;17(2):233-8. doi: 10.1634/theoncologist.2011-0205. Epub 2012 Jan 26.</citation>
    <PMID>22282904</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2007</study_first_submitted>
  <study_first_submitted_qc>January 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2007</study_first_posted>
  <results_first_submitted>May 20, 2013</results_first_submitted>
  <results_first_submitted_qc>May 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 9, 2013</results_first_posted>
  <last_update_submitted>May 20, 2013</last_update_submitted>
  <last_update_submitted_qc>May 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>GnRH Analogue</keyword>
  <keyword>Gonadotropin-releasing hormone analogue</keyword>
  <keyword>GnRH-a</keyword>
  <keyword>Ovarian Function</keyword>
  <keyword>Fertility</keyword>
  <keyword>Leuprolide Acetate</keyword>
  <keyword>Lupron Depot</keyword>
  <keyword>premature ovarian failure</keyword>
  <keyword>POF</keyword>
  <keyword>Abnormal suppression of menstruation</keyword>
  <keyword>absence of menstruation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amenorrhea</mesh_term>
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: November 18, 2002 to November 21, 2008. All participants were recruited in medical clinics.</recruitment_details>
      <pre_assignment_details>Of the 60 participants enrolled, one participant was excluded prior to treatment due to ineligibility.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Leuprolide Acetate</title>
          <description>Leuprolide Acetate 22.5 mg intramuscular (IM) injection 2 months before hematopoietic stem cell transplantation (HSCT) transplant and 3 months post-transplant.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Leuprolide Acetate</title>
          <description>Leuprolide Acetate 22.5 mg intramuscular (IM) injection 2 months before HSCT transplant and 3 months post-transplant.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25" lower_limit="17" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Secondary Amenorrhea Following 3-month Depot Leuprolide</title>
        <description>Hormonal profile blood tests including follicle-stimulating hormone (FSH) test, luteinizing hormone (LH) and estradiol levels done every two months with menstruation questionnaire, starting three months after the injection of the second dose of leuprolide until the restoration of spontaneous menstruation or the presence of ovarian failure. Any unexpected vaginal bleeding or side effects during the period covered by leuprolide injection, which is 6 months, is recorded by participants in a monitoring checklist sheet given to them.</description>
        <time_frame>6 months</time_frame>
        <population>Of the 59 patients who underwent HSCT, nine patients refused the second dose of leuprolide and were subsequently taken off study. Six patients died of either disease progression or transplantation-related complications before their ovarian function status was evaluated.</population>
        <group_list>
          <group group_id="O1">
            <title>Leuprolide Acetate</title>
            <description>Leuprolide Acetate 22.5 mg intramuscular (IM) injection 2 months before HSCT transplant and 3 months post-transplant.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Secondary Amenorrhea Following 3-month Depot Leuprolide</title>
          <description>Hormonal profile blood tests including follicle-stimulating hormone (FSH) test, luteinizing hormone (LH) and estradiol levels done every two months with menstruation questionnaire, starting three months after the injection of the second dose of leuprolide until the restoration of spontaneous menstruation or the presence of ovarian failure. Any unexpected vaginal bleeding or side effects during the period covered by leuprolide injection, which is 6 months, is recorded by participants in a monitoring checklist sheet given to them.</description>
          <population>Of the 59 patients who underwent HSCT, nine patients refused the second dose of leuprolide and were subsequently taken off study. Six patients died of either disease progression or transplantation-related complications before their ovarian function status was evaluated.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years and 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Leuprolide Acetate</title>
          <description>Leuprolide Acetate 22.5 mg intramuscular (IM) injection 2 months before HSCT transplant and 3 months post-transplant.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menopausal side effects</sub_title>
                <description>Menopausal side effects, including hot flushing, vaginal dryness, and mood swings</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Naoto T. Ueno, MD, PhD / Professor</name_or_title>
      <organization>The University of Texas (UT) MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

